Cargando…

Microbial Identification Using DNA Target Amplification and Sequencing: Clinical Utility and Impact on Patient Management

Broad-range polymerase chain reaction (PCR) is increasingly used in patients with culture-negative infections; however, few studies have assessed the diagnostic utility of this test in this context. We performed a retrospective cohort study of patients who had clinical specimens sent for broad-range...

Descripción completa

Detalles Bibliográficos
Autores principales: Basein, Tinzar, Gardiner, Bradley J, Andujar Vazquez, Gabriela M, Joel Chandranesan, Andrew S, Rabson, Arthur R, Doron, Shira, Snydman, David R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284463/
https://www.ncbi.nlm.nih.gov/pubmed/30539032
http://dx.doi.org/10.1093/ofid/ofy257
_version_ 1783379339338842112
author Basein, Tinzar
Gardiner, Bradley J
Andujar Vazquez, Gabriela M
Joel Chandranesan, Andrew S
Rabson, Arthur R
Doron, Shira
Snydman, David R
author_facet Basein, Tinzar
Gardiner, Bradley J
Andujar Vazquez, Gabriela M
Joel Chandranesan, Andrew S
Rabson, Arthur R
Doron, Shira
Snydman, David R
author_sort Basein, Tinzar
collection PubMed
description Broad-range polymerase chain reaction (PCR) is increasingly used in patients with culture-negative infections; however, few studies have assessed the diagnostic utility of this test in this context. We performed a retrospective cohort study of patients who had clinical specimens sent for broad-range PCR, aiming to evaluate performance and determine impact on patient management. Organisms were identified in 21/71 samples. High numbers of polymorphonuclear leukocytes on Gram stain (odds ratio [OR], 4.17; P = .04) and acute inflammation on histopathology (OR, 5.69; P = .02) were significantly associated with a positive result. Management was altered in 18 patients, 11 with positive and 7 with negative results. Overall, broad-range PCR assay had the highest impact in patients with microscopic evidence of inflammation. Physicians ordering this complex, difficult to interpret, and expensive test should carefully consider all available clinical information on an individualized basis to optimize its performance.
format Online
Article
Text
id pubmed-6284463
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62844632018-12-11 Microbial Identification Using DNA Target Amplification and Sequencing: Clinical Utility and Impact on Patient Management Basein, Tinzar Gardiner, Bradley J Andujar Vazquez, Gabriela M Joel Chandranesan, Andrew S Rabson, Arthur R Doron, Shira Snydman, David R Open Forum Infect Dis Major Article Broad-range polymerase chain reaction (PCR) is increasingly used in patients with culture-negative infections; however, few studies have assessed the diagnostic utility of this test in this context. We performed a retrospective cohort study of patients who had clinical specimens sent for broad-range PCR, aiming to evaluate performance and determine impact on patient management. Organisms were identified in 21/71 samples. High numbers of polymorphonuclear leukocytes on Gram stain (odds ratio [OR], 4.17; P = .04) and acute inflammation on histopathology (OR, 5.69; P = .02) were significantly associated with a positive result. Management was altered in 18 patients, 11 with positive and 7 with negative results. Overall, broad-range PCR assay had the highest impact in patients with microscopic evidence of inflammation. Physicians ordering this complex, difficult to interpret, and expensive test should carefully consider all available clinical information on an individualized basis to optimize its performance. Oxford University Press 2018-10-10 /pmc/articles/PMC6284463/ /pubmed/30539032 http://dx.doi.org/10.1093/ofid/ofy257 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Major Article
Basein, Tinzar
Gardiner, Bradley J
Andujar Vazquez, Gabriela M
Joel Chandranesan, Andrew S
Rabson, Arthur R
Doron, Shira
Snydman, David R
Microbial Identification Using DNA Target Amplification and Sequencing: Clinical Utility and Impact on Patient Management
title Microbial Identification Using DNA Target Amplification and Sequencing: Clinical Utility and Impact on Patient Management
title_full Microbial Identification Using DNA Target Amplification and Sequencing: Clinical Utility and Impact on Patient Management
title_fullStr Microbial Identification Using DNA Target Amplification and Sequencing: Clinical Utility and Impact on Patient Management
title_full_unstemmed Microbial Identification Using DNA Target Amplification and Sequencing: Clinical Utility and Impact on Patient Management
title_short Microbial Identification Using DNA Target Amplification and Sequencing: Clinical Utility and Impact on Patient Management
title_sort microbial identification using dna target amplification and sequencing: clinical utility and impact on patient management
topic Major Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284463/
https://www.ncbi.nlm.nih.gov/pubmed/30539032
http://dx.doi.org/10.1093/ofid/ofy257
work_keys_str_mv AT baseintinzar microbialidentificationusingdnatargetamplificationandsequencingclinicalutilityandimpactonpatientmanagement
AT gardinerbradleyj microbialidentificationusingdnatargetamplificationandsequencingclinicalutilityandimpactonpatientmanagement
AT andujarvazquezgabrielam microbialidentificationusingdnatargetamplificationandsequencingclinicalutilityandimpactonpatientmanagement
AT joelchandranesanandrews microbialidentificationusingdnatargetamplificationandsequencingclinicalutilityandimpactonpatientmanagement
AT rabsonarthurr microbialidentificationusingdnatargetamplificationandsequencingclinicalutilityandimpactonpatientmanagement
AT doronshira microbialidentificationusingdnatargetamplificationandsequencingclinicalutilityandimpactonpatientmanagement
AT snydmandavidr microbialidentificationusingdnatargetamplificationandsequencingclinicalutilityandimpactonpatientmanagement